Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neuroendocrine Risk for PTSD in Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03973229
Recruitment Status : Recruiting
First Posted : June 4, 2019
Last Update Posted : January 22, 2021
Sponsor:
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Jennifer Stevens, Emory University

Tracking Information
First Submitted Date  ICMJE May 30, 2019
First Posted Date  ICMJE June 4, 2019
Last Update Posted Date January 22, 2021
Actual Study Start Date  ICMJE November 11, 2019
Estimated Primary Completion Date April 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 3, 2019)
  • Change in amygdala response to fearful faces stimuli [ Time Frame: Mid-cycle second cycle, Mid-cycle third cycle (each cycle is an average of 28 days) ]
    Responses to threat cues will be assessed by fMRI responses as participants view 15 blocks each of fearful face and neutral face stimuli, while amygdala reactivity is measured.
  • Change in amygdala response to fear conditioning task [ Time Frame: Mid-cycle second cycle, Mid-cycle third cycle (each cycle is an average of 28 days) ]
    Indicators of fear conditioning will be assessed by fMRI during the fear conditioning tasks. Deficits in fear inhibition have been present in persons with PTSD and during phases of the ovarian cycle.
  • Change in ventromedial prefrontal cortex (vmPFC) activation during the fear extinction task [ Time Frame: Mid-cycle second cycle, Mid-cycle third cycle (each cycle is an average of 28 days) ]
    Indicators of fear extinction will be assessed by fMRI during the fear extinction tasks. Fear extinction is impaired in persons with PTSD and depends on the vmPFC and its inhibition of amygdala responses to threat stimuli.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 3, 2019)
  • Change in PTSD checklist for DSM-5 (PCL-5) [ Time Frame: Baseline, Mid-cycle second cycle, Mid-cycle third cycle (each cycle is an average of 28 days) ]
    The severity of self-reported PTSD symptoms will be assessed with the PCL-5. The PCL-5 asks participants to recall the worst stressful event that is currently bothering them the most. Keeping this event in mind, participants respond to 20 questions indicating how bothered they have been by PTSD symptoms. Responses are on a 5-point scale, where 0 = not bothered at all and 4 = extremely bothered. Total raw scores range from 0 to 80 where higher scores indicate greater distress from PTSD symptoms.
  • Change in Beck Depression Inventory (BDI) [ Time Frame: Baseline, Mid-cycle second cycle, Mid-cycle third cycle (each cycle is an average of 28 days) ]
    The BDI-II is a 21-item instrument assessing depression. Respondents indicate how severe their feelings of depression symptoms are on a scale of 0 (not present) to 3 (most severe). Total raw scores range from 0 to 63, with higher scores indicating greater severity of depression.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Neuroendocrine Risk for PTSD in Women
Official Title  ICMJE The LOW E2 STUDY- Neuroendocrine Risk Mechanisms for Post-traumatic Stress Disorder in Women
Brief Summary

This study will test for effects of estradiol (E2) on PTSD symptoms and functional magnetic resonance imaging (fMRI) indicators of stress vulnerability, in naturally-cycling women who are not using hormonal birth control. Enrollment will be targeted to create three groups within two cohorts (early follicular phase and luteal phase):

  1. PTSD: Women who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for PTSD
  2. Trauma-Exposed (TC): Women matched for age and trauma exposure severity but without PTSD
  3. Healthy Control (HC): Women matched for age, but without trauma history or psychiatric disorder (self-reported)

Women will be recruited through Grady Trauma Project (GTP), a large longstanding study of civilian trauma and PTSD conducted at Grady Memorial Hospital in Atlanta, Georgia.

Detailed Description

The majority of Americans will experience a traumatic event during their lifetimes. However, women are twice as likely as men to experience negative psychiatric outcomes following trauma, including post-traumatic stress disorder (PTSD) and depression. The reason for the increased prevalence in women is unclear, partially because of the historical lack of investigation of females in both human and pre-clinical animal research. The researchers propose to investigate the role of sex hormones in contributing to women's risk for PTSD. The study will investigate relationships between trauma exposure and women's menstrual cycle, examining key events in the cycle, including menstruation, ovulation, and mood changes. The study will then examine relationships between the level of naturally-cycling estradiol (E2; the primary female sex hormone), and brain-based measures of stress vulnerability. This includes amygdala hyper-reactivity to threat.

The trial will study if trauma-exposed women with lower E2 levels during the luteal phase will report greater PTSD symptoms, and show more stress-vulnerable patterns of brain function. It will also examine the effects of exogenous application of estrogen on PTSD symptoms.

Women will begin tracking their cycle using a free and widely-used cycle-tracking smartphone app "Clue" for one full menstrual cycle.

  • For Study Aims 1 & 2 (N=120): Participants will be contacted on the first day of their menstrual period in the second cycle, and scheduled for an MRI with a 4-day window (early follicular phase). Participants will be randomized to begin with either the E2 or placebo patch. The will receive an E2 or placebo patch 1 day prior to the MRI visit, with a blood draw on the morning of the MRI visit (to assess hormone levels), 1 hour prior to scanning. On the first day of the third cycle (onset of menses), women will all be scheduled for their second MRI visit. Participants will experience the opposite condition from their first MRI scan. They will receive an E2 or placebo patch 1 day prior to the MRI visit in the afternoon, with a blood draw on the morning of the MRI visit, 1 hour prior to scanning.
  • For Study Aim 3 (N=120): Participants will begin daily urine ovulation tests on Day 11 of their cycle, and will record the results in Clue. When participants record a positive ovulation test during the second month of cycle monitoring, they will be contacted to schedule their MRI visit 5-7 days following ovulation (during the luteal phase). The experimental protocol will otherwise be the same as in Aims 1 and 2, with participants randomized to either E2 or placebo at the first visit and returning the next month for the other condition.

The scientific premise of this study is that low E2 may contribute to stress vulnerability in women. Findings may aid in the development of treatments that will enhance women's mental health outcomes following trauma.

Study Type  ICMJE Interventional
Study Phase  ICMJE Early Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:
Women will participate in one cycle with the estrogen patch and one cycle with the placebo patch. Each cohort will include 40 participants in each of the three study arms for a total of 240 participants.
Masking: Double (Participant, Investigator)
Masking Description:
Randomization will be double blind, with the key held by the study coordinator in a locked file. The study coordinator will do checks of appropriate enrollment to groups after each 20 participants, but no blind will be broken to individuals analyzing study data. Grady pharmacy services will also hold the randomization schedule, as they will dispense the appropriate patch at the appropriate time point.
Primary Purpose: Basic Science
Condition  ICMJE
  • PTSD
  • Trauma
Intervention  ICMJE
  • Drug: Estradiol patch
    Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.
  • Other: Placebo patch
    Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.
Study Arms  ICMJE
  • Experimental: Cohort 1: PTSD Receiving Estradiol then Placebo
    Participants with PTSD will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
    Interventions:
    • Drug: Estradiol patch
    • Other: Placebo patch
  • Experimental: Cohort 1: PTSD Receiving Placebo then Estradiol
    Participants with PTSD will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
    Interventions:
    • Drug: Estradiol patch
    • Other: Placebo patch
  • Active Comparator: Cohort 1: Trauma without PTSD Receiving Estradiol then Placebo
    Participants with trauma exposure will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
    Interventions:
    • Drug: Estradiol patch
    • Other: Placebo patch
  • Active Comparator: Cohort 1: Trauma without PTSD Receiving Placebo then Estradiol
    Participants with trauma exposure will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
    Interventions:
    • Drug: Estradiol patch
    • Other: Placebo patch
  • Active Comparator: Cohort 1: Healthy Controls Receiving Estradiol then Placebo
    Participants without trauma history or psychiatric disorder will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
    Interventions:
    • Drug: Estradiol patch
    • Other: Placebo patch
  • Active Comparator: Cohort 1: Healthy Controls Receiving Placebo then Estradiol
    Participants without trauma history or psychiatric disorder will will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
    Interventions:
    • Drug: Estradiol patch
    • Other: Placebo patch
  • Experimental: Cohort 2: PTSD Receiving Estradiol then Placebo
    Participants with PTSD will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
    Interventions:
    • Drug: Estradiol patch
    • Other: Placebo patch
  • Experimental: Cohort 2: PTSD Receiving Placebo then Estradiol
    Participants with PTSD will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
    Interventions:
    • Drug: Estradiol patch
    • Other: Placebo patch
  • Active Comparator: Cohort 2: Trauma Control Receiving Estradiol, then Placebo
    Participants with trauma exposure will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
    Interventions:
    • Drug: Estradiol patch
    • Other: Placebo patch
  • Active Comparator: Cohort 2: Trauma Control Receiving Placebo then Estradiol
    Participants with trauma exposure will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
    Interventions:
    • Drug: Estradiol patch
    • Other: Placebo patch
  • Active Comparator: Cohort 2: Healthy Control Receiving Estradiol then Placebo
    Participants without trauma history or psychiatric disorder will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
    Interventions:
    • Drug: Estradiol patch
    • Other: Placebo patch
  • Active Comparator: Cohort 2: Healthy Control Receiving Placebo then Estradiol
    Participants without trauma history or psychiatric disorder will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
    Interventions:
    • Drug: Estradiol patch
    • Other: Placebo patch
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: June 3, 2019)
240
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE April 2024
Estimated Primary Completion Date April 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • African American women
  • A menstrual period within the past 60 days
  • Able and willing to give informed consent
  • Must have a smart phone and willing to install the Clue app

Exclusion Criteria:

  • Women currently taking any form of hormone-based birth control or other hormonal supplement
  • Women who are pregnant or breastfeeding
  • Current psychoactive medication use, nicotine use or smoking
  • Hypercoagulable conditions, history of embolism, current symptoms of psychosis or bipolar disorder
  • History of major head injury or neurological disorder
  • Weight >250lbs (a maximum weight to allow for participants to fit comfortably inside the bore of the MRI machine) and typical physical contraindications for MRI such as metal implants
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years to 35 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Jennifer Stevens, PhD 404-778-1698 jennifer.stevens@emory.edu
Contact: Rebecca Hinrichs rebecca.hinrichs@emory.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03973229
Other Study ID Numbers  ICMJE IRB00103595
1R01MH117009-01A1 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: There is an agreement with the National Institute of Mental Health (NIMH) to share deidentified data with Research Domain Criteria (RDoC) database (a centralized NIH database). Raw neuroimaging data and behavioral data for the 3 tasks (Fearful Faces, Fear Conditioning, Fear Extinction), T1 structural brain images, non-identifying demographics, PCL-5, and BDI will be shared.
Supporting Materials: Study Protocol
Time Frame: Data will be uploaded to the database every 6 months following the standard NIH schedule (Jan 15 and July 15 of each year of funding). Data will be released publicly within 4 months after submission.
Access Criteria: Data access requests will be submitted to RDoC database, and approved by NIH before data are shared. Only research investigators sponsored by an NIH recognized institution with federal wide assurance will receive access. Any analysis approved by NIH. Web-based access to the RDoC data archive.
URL: https://nda.nih.gov/
Responsible Party Jennifer Stevens, Emory University
Study Sponsor  ICMJE Emory University
Collaborators  ICMJE National Institute of Mental Health (NIMH)
Investigators  ICMJE
Principal Investigator: Jennifer Stevens, PhD Emory University
PRS Account Emory University
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP